D-0345-2019 Class III Terminated

Recalled by Amerigen Pharmaceuticals Inc. — Lyndhurst, NJ

FDA drug recall D-0345-2019 was initiated by Amerigen Pharmaceuticals Inc. on Dec 20, 2018 and is designated Class III. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Dec 17, 2019). Affected quantity: 771 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 2, 2019
Initiation Date
Dec 20, 2018
Termination Date
Dec 17, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
771 bottles

Product description

Temozolomide Capsules, 180 mg, packaged in a 14 count bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ ---- NDC 43975-256-14

Reason for recall

Failed Dissolution Specifications

Distribution pattern

Product was distributed to 4 wholesalers and 2 retail accounts who may have further distributed the products.

Code information

Lot # 18E031, exp 05/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0345-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0345-2019. Report a data issue: hello@regdatalab.com.